Raadi | Blue Cross MN

Soo bandhiga 1991 - 2000 ee natiijooyinka 3613

Bixiye

QP77-20 Commercial Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Bempedoic Acid

Wax badan akhri

Taariikhda barnaamijka Dhaqangalayso Agosto 26, 2020

Bixiye

QP82-20 Commercial Pharmacy Benefit Exclusion for Amzeeq™ (minocycline) foam, brimonidine ophthalmic solution 0.15% and ProAir® (albuterol sulfate) HFA

Wax badan akhri

Taariikhda barnaamijka Dhaqangalayso Agosto 26, 2020

Bixiye

P40-20 New Medical, Medical Drug and Behavioral Health Policy Management Updates – Effective August 3, 2020

Wax badan akhri

Taariikhda wax ku ool ah ee barnaamijka: Jun 01, 2020

Bixiye

2020 September Provider Press

Wax badan akhri

Taariikhda barnaamijka Dhaqangalayso Agosto 19, 2020

Bixiye

QP76-20 Outlier Outpatient Therapy Management Program

Wax badan akhri

Taariikhda barnaamijka Dhaqangalayso Agosto 12, 2020

Bixiye

QP74-20 MHCP Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Isturisa PA with QL

Wax badan akhri

Taariikhda barnaamijka Dhaqangalayso Agosto 12, 2020

Bixiye

QP73-20 MHCP Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Bempedoic Acid PA with QL

Wax badan akhri

Taariikhda barnaamijka Dhaqangalayso Agosto 12, 2020

Bixiye

QP72-20 MHCP Pharmacy Benefit Update – Pharmacy Benefit Exclusion for Anjeso™, Fetroja®, Herzuma®, Ontruzant®, Potassium Phosphates, Scenesse® and Trazimera™

Wax badan akhri

Taariikhda barnaamijka Dhaqangalayso Agosto 12, 2020

Bixiye

QP71-20 MHCP Pharmacy Benefit Update: Pharmacy Benefit Exclusion for Phesgo™, Uplizna™, and Zepzelca™

Wax badan akhri

Taariikhda barnaamijka Dhaqangalayso Agosto 12, 2020

Bixiye

QP75-20 Commercial Pharmacy Benefit Exclusion for Aralast®NP, Eylea®, Glassia®, Lucentis®, Prolastin®-C, and UpliznaTM

Wax badan akhri

Taariikhda barnaamijka Dhaqangalayso Agosto 12, 2020